# Mylan Institutional, a Viatris Company: Iron Sucrose Injection to be discontinued

**Score:** 60/100

| Field | Value |
|---|---|
| Manufacturer | Mylan Institutional, a Viatris Company |
| Drug | Iron Sucrose Injection |
| Dosage form | Injection |
| Therapeutic category | Hematology |
| Status | To Be Discontinued |
| Stage | Manufacturer discontinuation |
| Presentations affected | 1 |
| Package NDCs | 67457-957-99 |
| Manufacturer supply note | A business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10 Iron Sucrose 20mg/mL 5mL SDV 10PK 67457-638-25 Iron Sucrose 20mg/mL 5mL SDV 25PK. |
| Discontinued date | 2026-05-21 |
| First posted | 2026-05-21 |
| Updated | 2026-05-21 |

## Why this score
- The manufacturer is leaving the market.
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.